Berliner Boersenzeitung - The scientist rewriting DNA, and the future of medicine

EUR -
AED 4.316068
AFN 75.78368
ALL 95.590345
AMD 433.921011
ANG 2.103199
AOA 1078.693153
ARS 1639.785212
AUD 1.624081
AWG 2.115085
AZN 1.998447
BAM 1.953692
BBD 2.367425
BDT 144.224377
BGN 1.960098
BHD 0.443342
BIF 3496.940129
BMD 1.175047
BND 1.48805
BOB 8.122098
BRL 5.804148
BSD 1.175422
BTN 110.788156
BWP 15.737751
BYN 3.321717
BYR 23030.922895
BZD 2.364009
CAD 1.602171
CDF 2720.234209
CHF 0.915114
CLF 0.026583
CLP 1046.250228
CNY 7.992494
CNH 7.994215
COP 4395.921653
CRC 539.208999
CUC 1.175047
CUP 31.138748
CVE 110.718804
CZK 24.309497
DJF 208.829292
DKK 7.472536
DOP 69.974145
DZD 155.20245
EGP 61.946583
ERN 17.625706
ETB 184.837228
FJD 2.569065
FKP 0.864214
GBP 0.865099
GEL 3.14908
GGP 0.864214
GHS 13.242649
GIP 0.864214
GMD 85.778323
GNF 10313.979512
GTQ 8.975086
GYD 245.920458
HKD 9.203498
HNL 31.268177
HRK 7.538985
HTG 153.949298
HUF 356.459886
IDR 20367.502417
ILS 3.409229
IMP 0.864214
INR 110.911284
IQD 1539.311683
IRR 1542719.319578
ISK 143.802053
JEP 0.864214
JMD 185.140228
JOD 0.833171
JPY 184.059961
KES 151.757262
KGS 102.723202
KHR 4714.873056
KMF 492.344575
KPW 1057.555194
KRW 1710.72734
KWD 0.361773
KYD 0.979526
KZT 544.33643
LAK 25792.283247
LBP 105225.46686
LKR 378.490323
LRD 215.562468
LSL 19.235691
LTL 3.469608
LVL 0.710774
LYD 7.437674
MAD 10.742863
MDL 20.222835
MGA 4894.071095
MKD 61.679754
MMK 2467.412574
MNT 4207.19177
MOP 9.480809
MRU 46.925498
MUR 54.88696
MVR 18.1603
MWK 2046.931705
MXN 20.277164
MYR 4.59457
MZN 75.083217
NAD 19.235747
NGN 1598.816408
NIO 43.130063
NOK 10.920412
NPR 177.26371
NZD 1.972799
OMR 0.451806
PAB 1.175412
PEN 4.062727
PGK 5.099342
PHP 71.029227
PKR 327.365667
PLN 4.227866
PYG 7194.237187
QAR 4.280702
RON 5.263274
RSD 117.383642
RUB 87.720656
RWF 1716.15627
SAR 4.436151
SBD 9.438281
SCR 16.52231
SDG 705.619296
SEK 10.86037
SGD 1.48966
SHP 0.877291
SLE 28.907303
SLL 24640.145375
SOS 671.539675
SRD 43.983217
STD 24321.10228
STN 24.999127
SVC 10.284902
SYP 129.899463
SZL 19.235297
THB 37.88334
TJS 10.984361
TMT 4.124415
TND 3.371797
TOP 2.829232
TRY 53.167497
TTD 7.951285
TWD 36.887663
TZS 3052.181577
UAH 51.470562
UGX 4396.218926
USD 1.175047
UYU 46.999286
UZS 14247.445607
VES 583.06901
VND 30915.488845
VUV 138.765659
WST 3.186155
XAF 655.238824
XAG 0.014727
XAU 0.000249
XCD 3.175623
XCG 2.118351
XDR 0.815968
XOF 653.912644
XPF 119.331742
YER 280.367229
ZAR 19.270304
ZMK 10576.837589
ZMW 22.391458
ZWL 378.364682
  • RBGPF

    0.0000

    63.18

    0%

  • BCC

    -1.4800

    72.76

    -2.03%

  • CMSD

    0.0000

    23.42

    0%

  • CMSC

    -0.0400

    22.97

    -0.17%

  • RELX

    -1.5900

    34.16

    -4.65%

  • NGG

    -1.9400

    85.91

    -2.26%

  • BCE

    0.3400

    24.57

    +1.38%

  • RYCEF

    -0.0500

    17.45

    -0.29%

  • RIO

    -2.4000

    103.11

    -2.33%

  • GSK

    -0.0300

    50.5

    -0.06%

  • JRI

    -0.0200

    13.15

    -0.15%

  • BTI

    -1.4800

    58.08

    -2.55%

  • AZN

    -2.4000

    182.52

    -1.31%

  • BP

    -0.8200

    43.81

    -1.87%

  • VOD

    -0.4400

    15.69

    -2.8%

The scientist rewriting DNA, and the future of medicine
The scientist rewriting DNA, and the future of medicine / Photo: Casey ATKINS - Broad Institute of Harvard and MIT,/AFP

The scientist rewriting DNA, and the future of medicine

A revolution is underway in gene editing -- and at its forefront is David Liu, an American molecular biologist whose pioneering work is rewriting the building blocks of life with unprecedented precision.

Text size:

A professor at the Broad Institute of MIT and Harvard, Liu was awarded a Breakthrough Prize in Life Sciences on Saturday for developing two transformative technologies: one already improving the lives of patients with severe genetic diseases, the other poised to reshape medicine in the years ahead.

He spoke with AFP ahead of the Los Angeles ceremony for the prestigious Silicon Valley-founded award.

He will receive $3 million for his work on "base editing" and "prime editing," and plans to donate most of it to support his charitable foundation.

"The ability to change a DNA sequence of our choosing into a new sequence of our choosing is a fundamentally very powerful capability," the 51-year-old said, foreseeing uses not just in human medicine but areas like developing more nutritious or disease-resistant crops.

- Correcting the code -

DNA is made up of four chemical "letters" -- the nucleotide bases A, G, T and C. Mutations in this sequence cause thousands of human diseases, yet until recently, gene editing could only fix a limited number of them.

Even CRISPR-Cas9, the groundbreaking technology that earned a Nobel Prize in 2020, has major limitations.

It cuts both strands of the DNA helix, making it most useful to disrupt rather than correct genes, while the process can introduce new errors.

"Being able to use genome editing to treat genetic diseases requires, in most cases, ways to correct a DNA misspelling, not simply to disrupt a gene," Liu said.

That insight led his lab to develop base editing, which uses the Cas9 protein -- disabled so it can no longer cut both DNA strands -- to find a target DNA sequence and another enzyme to convert one letter to another -- for example, C to T or G to A.

Reversing the change -- from T to C or A to G -- was tougher. Liu's team overcame the challenge by engineering entirely new enzymes.

These base editors can now correct about 30 percent of the mutations that cause genetic diseases. The technology is already in at least 14 clinical trials.

In one of them, Beam Therapeutics -- which Liu co-founded -- announced it had treated patients of AATD, a rare genetic disorder affecting the lungs and liver, with a single drug infusion.

While traditional gene therapies often disrupt faulty genes or work around them, base editing repairs the mutation itself.

"This was the first time that humans have corrected a mutation that causes a genetic disease in a patient," Liu said.

- Cystic fibrosis hope -

Base editing, quickly dubbed "CRISPR 2.0," can't fix every mutation.

About 70 percent of the roughly 100,000 known disease-causing mutations remain out of its reach, including those caused by missing or extra letters.

To expand the toolkit, Liu's lab introduced prime editing in 2019 -- a method capable of replacing entire sections of faulty DNA with corrected sequences.

If CRISPR is like scissors that cut DNA, and base editors are like using a pencil to correct individual letters, then prime editing is the equivalent of a word processor's "find and replace" function.

Creating this tool required a series of breakthroughs Liu's team describes as "small miracles." The result is, he said, "the most versatile way we know of to edit the human genome."

Among the targets Liu and his team have already pursued with prime editing: cystic fibrosis, a common genetic disease usually caused by three missing DNA letters that causes thick mucus buildup in the lungs and digestive system.

Liu's lab has made much of its work freely accessible, sharing DNA blueprints through a nonprofit library used by tens of thousands of labs worldwide.

"The science we create -- which is ultimately funded by society, through governments and donors -- ultimately goes back to benefit society."

This year's Breakthrough Prize awards come at a fraught moment for US science, as President Donald Trump's government strips funding for institutions like the National Institutes of Health (NIH).

"The NIH is a treasure, not just for this country but for the world," said Liu. "Trying to dismantle the heart of what supports science in this country is like burning your seed corn."

(K.Müller--BBZ)